Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Tim Wilsdon"'
Publikováno v:
Frontiers in Public Health, Vol 11 (2023)
Strong evidence of lung cancer screening’s effectiveness in mortality reduction, as demonstrated in the National Lung Screening Trial (NLST) in the US and the Dutch–Belgian Randomized Lung Cancer Screening Trial (NELSON), has prompted countries t
Externí odkaz:
https://doaj.org/article/014cabf56e9a4a8cb91c06f5f2637a0b
Autor:
Khalid A. Alnaqbi, Agnès Bellanger, Alex Brill, Gilberto Castañeda-Hernández, Ana Clopés Estela, Olga Delgado Sánchez, Pilar García-Alfonso, Pius Gyger, Daniel Heinrich, Germain Hezard, Adriana Kakehasi, Cheryl Koehn, Olivier Mariotte, Francesco Mennini, Sonia Mayra Pérez-Tapia, Michele Pistollato, Rowan Saada, Tadanori Sasaki, George Tambassis, Marc Thill, Gustavo Werutsky, Tim Wilsdon, Steven Simoens
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Although biosimilar uptake has increased (at a variable pace) in many countries, there have been recent concerns about the long-term sustainability of biosimilar markets. The aim of this manuscript is to assess the sustainability of polic
Externí odkaz:
https://doaj.org/article/21e2850e32424b76ad1f5aed8e8e32e0
Publikováno v:
Health Policy. 126:956-969
Approaches to routine vaccine funding and the underlying budget-setting process vary greatly across European countries. The ongoing COVID-19 pandemic has put enormous pressure on healthcare systems, affecting resilience of the overall vaccine ecosyst
Publikováno v:
The Journal of World Intellectual Property. 23:609-631
This article discusses the potential impact of reforming Argentina's innovation policy on innovative and economic activity, drawing from evidence of case study markets. We review existing evidence on the relationship between changes in innovation pol
Publikováno v:
Expert Review of Vaccines. 19:123-132
Introduction: Across Europe, immunization programs have brought immense benefits to the prevention of infectious diseases. The vaccines used are procured through a variety of models such as tenders and Pricing & Reimbursement. However, to date, the i
Publikováno v:
Health Policy. 123:652-660
There is widespread concern regarding the high price of innovative medicines and their impact on the sustainability of healthcare systems. However, the debate rarely accounts for the evolution of prices over the lifetime of the medicine and the impac
Publikováno v:
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
Journal of Market Access & Health Policy
article-version (VoR) Version of Record
Journal of Market Access & Health Policy
article-version (VoR) Version of Record
Background: In recent years, innovation in oncology has created new challenges for pricing and reimbursement systems. Oncology medicines with multiple indications face a number of access challenges: (1) the number of assessments and administrative bu
Publikováno v:
SSRN Electronic Journal.
Autor:
Agustin Azcatl Romero, Alberto Villalobos, Alejandra del Río, Alejandro Javier Cafiero, Alejandro M. O. Croci, Alfredo Silverio Gusman, Ana María Castro, Andrés Brandolini, Armando Arenas Reyes, Cristian Bittel, Cristóbal González, Eduardo Arana Ramírez, Eric Edgardo Velasco Caballero, Fernando García, Francisco Gallegos, Freddy Arias Mora, Gabriel Kuri, Galit Gonen Cohen, Gustavo de Freitas Morais, Ignacio Gilmore, Jessica Ugas Bernedo, Jorge Méndez, José Humberto Deveza Assola, Karin Gómez Girón, Karina Loza Santillán, Leonardo Alonso, Marcelo Cases, Marco Antonio Palacios, Maria Cecilia Romoleroux, Maricruz Cepeda Torres, Maritza Reátegui Valdiviezo, Mary Fernández, Monique Rodrigues Teixeira, Rodolfo Godoy, Rodrigo Augusto Oliveira Rocci, Romina J. Glisoni, Sebastián Meythaler Galarza, Tim Wilsdon, Xavier Rosales, Zayde Chahín Rozo
Esta obra es una herramienta útil en la tarea de apoyar y divulgar el conocimiento de los temas que hacen a una adecuada comprensión del valor de la propiedad industrial e intelectual como agente promotor del crecimiento y de sus pilares fundamenta
Autor:
Anthony Barron, Tim Wilsdon
Publikováno v:
Pharmaceutical Medicine
Although significant progress has been made in the past decade in the treatment of both common and rare cancers, there has been significant concerns about the cost, and especially the value, of certain new oncology drugs. These concerns touch upon a